Turn Therapeutics (TTRX) Liabilities and Shareholders Equity (2024 - 2026)

Turn Therapeutics' Liabilities and Shareholders Equity history runs 3 years deep, the most recent figure standing at $18.6 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity changed N/A year-over-year to $18.6 million in Q1 2026; TTM through Mar 2026 was $35.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $12.2 million, up 493.6% from the prior year.
• Liabilities and Shareholders Equity advanced to $18.6 million in Q1 2026 per TTRX's latest filing, from $12.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $18.6 million in Q1 2026 and bottomed at $2.0 million in Q4 2024.
• The 3-year median for Liabilities and Shareholders Equity is $8.2 million (2025), against an average of $9.3 million.
• Biggest YoY gain for Liabilities and Shareholders Equity was 493.6% in 2025; the steepest drop was 493.6% in 2025.
• Year by year, Liabilities and Shareholders Equity stood at $2.0 million in 2024, then jumped by 493.6% to $12.2 million in 2025, then jumped by 53.3% to $18.6 million in 2026.
• Per Business Quant, the three latest TTRX Liabilities and Shareholders Equity figures stand at $18.6 million (Q1 2026), $12.2 million (Q4 2025), and $4.3 million (Q3 2025).